Y-Intercept (Hong Kong) 13F: New $25M Stake in ABT
Y-Intercept (Hong Kong) has taken a new position in Abbott Laboratories, acquiring 250,717 shares valued at approximately $24.8 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Y-Intercept (Hong Kong) opened a new position of 250,717 shares in Abbott Laboratories ($ABT), according to a 13F filing with the SEC dated October 16, 2026. It reported 250,717 shares worth $24.78 million at the end of the quarter.
Find the original: Y-Intercept (Hong Kong) 13F filings on SEC EDGAR
ABT
Abbott Laboratories
Key Points
- Y-Intercept (Hong Kong) has acquired 250,717 shares of Abbott Laboratories (NYSE: ABT), marking a new position valued at about $24.8 million.
- As of October 16, 2026, Abbott's stock trades at approximately $104.70, below its 50-day moving average and significantly under its 52-week high.
- Analysts generally rate Abbott Laboratories as a strong buy, with a mean price target of $120.71, suggesting room for growth.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Y-Intercept (Hong Kong) has taken a new position in Abbott Laboratories (NYSE: ABT), acquiring 250,717 shares valued at approximately $24.8 million in a filing on October 16, 2026. This new stake highlights the fund's interest in Abbott, known for its medical devices and healthcare products.
What Changed in Y-Intercept's Abbott Position
Y-Intercept opened a brand-new position in Abbott Laboratories, adding 250,717 shares. The total value of this stake is around $24,778,361. This move shows the fund's growing confidence in Abbott's potential.
Other Institutional Activity in Abbott Laboratories
Several other institutional investors have maintained their positions in Abbott. Blackrock Inc. holds 152,563,476 shares valued at about $16 billion after increasing its stake by 6,876,428 shares. Vanguard Capital Management LLC has 113,750,994 shares worth around $11.9 billion, having added 801,938 shares. State Street Corporation also increased its holdings, adding 1,352,749 shares for a total of approximately 80.9 million shares valued at about $8.5 billion.
Abbott Laboratories Stock Up 2.3%
As of October 16, 2026, Abbott Laboratories trades at about $104.70, which is below its 50-day moving average of $105.93. The stock is also about 20.7% below its 52-week high of $132.03, indicating potential for recovery if conditions improve. Meanwhile, the stock is above its 52-week low of $81.97.
Recent Earnings
For the trailing twelve months ending September 30, 2026, Abbott reported revenue of approximately $46.6 billion and earnings per share of $3.10. The company has shown solid growth, with a year-over-year revenue growth rate of 13.0%. Abbott is set to report its next earnings on October 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Abbott Laboratories
Recent insider activity at Abbott includes Director John G. Stratton, who purchased 2,000 shares on May 7, 2026, at an average price of $86.82, totaling around $173,640. Other insiders, such as Officer Louis H. Morrone and CEO Robert B. Ford, have sold shares in recent months.
Analysts Set New Price Targets
On October 16, 2026, TD Cowen reiterated a buy rating for Abbott Laboratories with a price target of $135. Earlier in the month, Rothschild & Co upgraded its rating to buy with a target of $127. The consensus among analysts remains strong, with a mean target price of $120.71 based on 26 opinions.
About Abbott Laboratories
Abbott Laboratories develops and sells various healthcare products globally, including medical devices, diagnostic tools, and nutritional products. Its operations are crucial in the healthcare sector, focusing on improving patient outcomes. The recent filing shows that Y-Intercept is keen on this sector's potential for growth.
Bottom Line
Y-Intercept's recent filing indicates a new investment strategy as it moves into Abbott Laboratories. The fund's recent moves and the upcoming earnings report on October 21 could provide further insights into Abbott's prospects. Keep in mind that this filing reflects holdings as of the reporting period and may not represent the investor's current position. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Y-Intercept (Hong Kong)'s 13F filing on $ABT (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Y-Intercept (Hong Kong) 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts